Full Text Journal Articles in
Journal Prostate

Advertisement

Find full text journal articles






Cell-cycle risk score more accurately determines the risk for metastases and death in prostatectomy patients compared with clinical features alone.

Gregory P Swanson, Lauren Lenz, Steven Stone, Todd Cohen,

<h4>Background</h4>Prostate cancer treatment aims to prevent metastases and disease-specific mortality. Pathologic parameters have limited ability to predict these outcomes, but biomarkers can improve risk discrimination. We evaluated the ability of cell-cycle progression and combined cell-cycle risk scores to predict metastases and disease-specific mortality after prostatectomy.<h4>Methods</h4>Eligibility included (1) treatment with radical ... Read more >>

Prostate (The Prostate)
[2021, :]

Cited: 0 times

View full text PDF listing >>



A new flavonoid derivative exerts antitumor effects against androgen-sensitive to cabazitaxel-resistant prostate cancer cells.

Renato Naito, Hiroshi Kano, Takashi Shimada, Tomoyuki Makino, Suguru Kadomoto, Hiroaki Iwamoto, Hiroshi Yaegashi, Kouji Izumi, Yoshifumi Kadono, Hiroki Nakata, Yohei Saito, Masuo Goto, Kyoko Nakagawa-Goto, Atsushi Mizokami,

<h4>Background</h4>Our previous report has shown that the flavonoid 2'-hydroxyflavanone (2'-HF) showed inhibition of androgen receptor (AR) activity against androgen-sensitive prostate cancer (PCa) cells, LNCaP, and exhibited antitumor effects against androgen-insensitive PCa cells, PC-3, and DU145. In the present study, we prepared a derivative of 2'-HF, 16MS7F1924, and confirmed the effects ... Read more >>

Prostate (The Prostate)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Oncologic outcome of radical prostatectomy versus radiotherapy as primary treatment for high and very high risk localized prostate cancer.

Ahmed Emam, Gregory Hermann, Kristopher Attwood, Wenyan Ji, Gaybrielle James, Michael Kuettel, James L Mohler,

<h4>Objective</h4>To compare the oncologic outcomes of radical prostatectomy (RP) versus external beam radiotherapy (EBRT) ± androgen deprivation therapy for primary treatment of high risk localized prostate cancer (CaP).<h4>Methods</h4>We retrospectively reviewed a prospectively-populated database for cases who underwent primary treatment for high risk localized CaP, had more than 2 years follow-up, and were treated since ... Read more >>

Prostate (The Prostate)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Prostate-to-bladder cross-sensitization in a model of zymosan-induced chronic pelvic pain syndrome in rats.

Ozgu Aydogdu, Pinar Uyar Gocun, Patrik Aronsson, Thomas Carlsson, Michael Winder,

<h4>Background</h4>The aim of the present study was to investigate the effects of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) on bladder function and pathophysiology.<h4>Methods</h4>To create a model for CPPS, rats were intraprostatically injected with zymosan or saline, serving as control. Metabolic cage experiments were performed 7, 14, or 21 days after ... Read more >>

Prostate (The Prostate)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.

Panagiotis J Vlachostergios, Muhammad Junaid Niaz, Myrto Skafida, Seyed Ali Mosallaie, Charlene Thomas, Paul J Christos, Joseph R Osborne, Ana M Molina, David M Nanus, Neil Harrison Bander, Scott T Tagawa,

<h4>Background</h4>Prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) has demonstrated efficacy and tolerability with a dose-response effect in phase I/II trials in men with metastatic castration-resistant prostate cancer (mCRPC). The need for positive PSMA imaging before PSMA-TRT to select patients is largely practiced, but its utility is not proven. Given target ... Read more >>

Prostate (The Prostate)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Prostatic ductal adenocarcinoma variant predicts worse pathological and oncological outcomes: Insight from over 1000 consecutive patients from a large prospective uro-oncology registry.

Yu Guang Tan, Farhan Khalid, Hong Hong Huang, Kenneth Chen, Kae Jack Tay, Weber K O Lau, Christopher W S Cheng, Nye Thane Ngo, John S P Yuen,

<h4>Objective</h4>To evaluate if prostatic ductal adenocarcinoma (PDA) independently predicts poorer pathological and oncological outcomes after radical prostatectomy (RP).<h4>Methods and materials</h4>Utilizing a large prospective uro-oncology registry, clinicopathological parameters of 1027 consecutive patients who underwent RP (2008-2017) were recorded. Oncological outcomes were determined by failure to achieve unrecordable PSA postoperatively and biochemical ... Read more >>

Prostate (The Prostate)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Role of Runx2 in prostate development and stem cell function.

Yan Li, Chunxi Ge, Renny T Franceschi,

<h4>Background</h4>RUNX2, a critical transcription factor in bone development, is also expressed in prostate and breast where it has been linked to cancer progression and cancer stem cells. However, its role in normal prostate biology has not been previously examined.<h4>Methods</h4>Selective growth of murine prostate epithelium under non-adherent conditions was used to ... Read more >>

Prostate (The Prostate)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Prostate and testicular growth analysis in human fetuses during the second gestational trimester.

Natasha T Logsdon, Carla M Gallo, Rodrigo S Pires, Francisco J Sampaio, Luciano A Favorito,

<h4>Background</h4>The second gestational trimester is a very important period for male genital development. We analyzed the testicular and prostatic volume growth and compared them to the biometric parameters in human fetuses.<h4>Methods</h4>We studied 64 testes and 32 prostates from 32 fetuses, aged 10-22 weeks postconception. Fetuses were evaluated regarding total length, ... Read more >>

Prostate (The Prostate)
[2021, 81(3):214-219]

Cited: 0 times

View full text PDF listing >>



TALEN-mediated generation of Nkx3.1 knockout rat model.

Ji Min Lee, Ukjin Kim, Hyokyung Yang, Bokyeong Ryu, Jin Kim, Tetsushi Sakuma, Takashi Yamamoto, Jae-Hak Park,

<h4>Background</h4>Recent developments in gene editing, using transcriptional activator-like effector nucleases (TALENs), have greatly helped the generation of genetically engineered animal models. The NK3 homeobox 1 (NKX3.1) protein plays important roles in prostate development and protein production, and functions as a tumor suppressor. Recently, NKX3.1 was shown to be associated with ... Read more >>

Prostate (The Prostate)
[2021, 81(3):182-193]

Cited: 0 times

View full text PDF listing >>



Risk of major adverse cardiovascular events among second-line hormonal therapy for metastatic castration-resistant prostate cancer: A real-world evidence study.

Jui-Ming Liu, Cheng-Chia Lin, Miao-Fen Chen, Kuan-Lin Liu, Cheng-Feng Lin, Tien-Hsing Chen, Chun-Te Wu,

<h4>Background</h4>To evaluate the possible major adverse cardiovascular events (MACE) associated with second-line hormonal therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).<h4>Methods</h4>We performed a population-based real-world cohort study of 4962 prostate cancer patients between 2014 and 2017 utilizing the Chang Gung Research Database of Taiwan. The second-line hormonal therapies included ... Read more >>

Prostate (The Prostate)
[2021, 81(3):194-201]

Cited: 0 times

View full text PDF listing >>



Prostate cancer C5a receptor expression and augmentation of cancer cell proliferation, invasion, and PD-L1 expression by C5a.

Ryuji Imamura, Saki Kitagawa, Tatsuko Kubo, Atsushi Irie, Toru Kariu, Masakazu Yoneda, Tomomi Kamba, Takahisa Imamura,

<h4>Background</h4>The treatment of castration-resistant prostate cancer (CRPC) is a urological issue. Recent studies have revealed cancer promotion via the C5a-C5a receptor (C5aR) system. To establish a new therapeutic target for CRPC, we investigated an association of the system with CRPC progression and evasion from the antitumor immune responses.<h4>Methods</h4>C5aR and PD-L1 ... Read more >>

Prostate (The Prostate)
[2021, 81(3):147-156]

Cited: 0 times

View full text PDF listing >>



Knowledge of prostate cancer among African American men: A systematic review.

Steven S Coughlin, Marlo Vernon, Zachary Klaassen, Martha S Tingen, Jorge E Cortes,

<h4>Objective</h4>Recent studies indicate that many African American men may not be making informed decisions about prostate cancer early detection. This is partly due to patients having limited knowledge about early detection of the disease.<h4>Methods</h4>The present review is based upon bibliographic searches in PubMed and CINAHL and relevant search terms. Articles ... Read more >>

Prostate (The Prostate)
[2021, 81(3):202-213]

Cited: 0 times

View full text PDF listing >>



Promoting cell proliferation, cell cycle progression, and glycolysis: Glycometabolism-related genes act as prognostic signatures for prostate cancer.

Yao Zhang, Yanhua Mou, Chao Liang, Shenhao Zhu, Shouyong Liu, Pengfei Shao, Jie Li, Zengjun Wang,

<h4>Background</h4>The Warburg effect seen in most solid tumors occurs only in the late stages of prostate cancer (PCa). Currently, the management of patients with low-risk localized PCa and patients after radical therapy remains a challenge. Our objective here was to evaluate glycometabolism-related genes as prognostic signatures for PCa.<h4>Methods</h4>The International Cancer ... Read more >>

Prostate (The Prostate)
[2021, 81(3):157-169]

Cited: 1 time

View full text PDF listing >>



O-glycosylated clusterin as a sensitive marker for diagnosing early stages of prostate cancer.

Saiko Kazuno, Tsutomu Fujimura, Makoto Fujime, Yoshiki Miura, Takashi Ueno,

<h4>Background</h4>Prostate-specific antigen (PSA) has been the most popular diagnostic marker for prostate cancer. The frequent occurrence of low PSA values (<10 ng/ml) in patients with highly suspicious prostate cancer, however, has undermined the accuracy of clinical examinations. The aim of this study was to develop a better resolution for diagnosing prostate ... Read more >>

Prostate (The Prostate)
[2021, 81(3):170-181]

Cited: 0 times

View full text PDF listing >>



The characteristics and spatial distributions of prostate cancer in autopsy specimens.

Yi Zhou, Zhipeng Mai, Weigang Yan, Yuliang Chen, Zhien Zhou, Yu Xiao, Wenze Wang, Zhiyuan Shang, Runqiang Yuan, Zhigang Ji, Hanzhong Li,

<h4>Background</h4>The characteristics of prostate cancer on autopsy and early-stage prostate cancer are identical. Using autopsy specimens, we analysed prostate cancer characteristics and clarified the spatial distributions of lesions.<h4>Method</h4>We obtained prostate specimens from Chinese donors without a prostate cancer diagnosis and analyzed prostate cancer pathological characteristics on autopsy by whole-mount sampling. ... Read more >>

Prostate (The Prostate)
[2021, 81(2):135-141]

Cited: 0 times

View full text PDF listing >>



Prostate specific membrane antigen (PSMA): A novel modulator of p38 for proliferation, migration, and survival in prostate cancer cells.

Yiming Zhang, Zhenghui Guo, Tao Du, Jieqing Chen, Wei Wang, Kewei Xu, Tianxin Lin, Hai Huang,

Prostate (The Prostate)
[2021, 81(2):142-143]

Cited: 0 times

View full text PDF listing >>



CT-based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration-naïve oligometastatic prostate cancer.

Sara Sheikhbahaei, Diane K Reyes, Steven P Rowe, Kenneth J Pienta,

<h4>Background</h4>The purpose of this study is to assess the body composition changes in men with recently diagnosed oligometastatic prostate cancer following neoadjuvant chemohormonal therapy. Further, we evaluated whether CT-based body composition parameters are associated with biochemical recurrence or imaging progression.<h4>Material and methods</h4>Recently diagnosed castration-naïve oligometastatic prostate cancer patients who received ... Read more >>

Prostate (The Prostate)
[2021, 81(2):127-134]

Cited: 0 times

View full text PDF listing >>



Early-onset prostate cancer is associated with increased risks of disease progression and cancer-specific mortality.

Hung-Jen Shih, Su-Chen Fang, Lu An, Yu-Hsuan J Shao,

<h4>Objective</h4>Prostate cancer (PCa) incidence has stabilized but not in patients at a young age. We assessed patient characteristics and disease progression in early-onset PCa.<h4>Methods</h4>A retrospective cohort of 28,039 newly diagnosed PCa patients aged ≥35 years was constructed using the Taiwan Cancer Registry in 2008-2016. Patients were categorized by age at ... Read more >>

Prostate (The Prostate)
[2021, 81(2):118-126]

Cited: 0 times

View full text PDF listing >>



TMPRSS2-ERG fusion impacts anterior tumor location in men with prostate cancer.

Kosj Yamoah, Priti Lal, Shivanshu Awasthi, Arash O Naghavi, Robert J Rounbehler, Travis Gerke, Anders E Berglund, Julio M Pow-Sang, Edward M Schaeffer, Jasreman Dhillon, Jong Y Park, Timothy R Rebbeck,

<h4>Background</h4>In prostate cancer (PCa), lack of androgen receptor (AR) regulated TMPRSS2-ETS-related gene (ERG) gene fusion (ERG<sup>negative</sup> ) status has been associated with African American race; however, the implications of ERG status for the location of dominant tumors within the prostate remains understudied.<h4>Methods</h4>An African American-enriched multiinstitutional cohort of 726 PCa patients ... Read more >>

Prostate (The Prostate)
[2021, 81(2):109-117]

Cited: 0 times

View full text PDF listing >>



Activated autophagy restored the impaired frequency and function of regulatory T cells in chronic prostatitis.

Yi Liu, Yong Zhang, Meng Zhang, Jialin Meng, Qingqing Ma, Zongyao Hao, Meijuan Zheng, Li Zhang, Xianguo Chen, Chaozhao Liang,

<h4>Background</h4>Chronic prostatitis or chronic pelvic pain syndrome (CP/CPPS) is a disease with an unclear pathogenesis. Recent studies have reported that regulatory T (Treg) cells might be involved in the development of CP/CPPS. In this study we aimed to examine the functional role of Treg cells and explore the possible regulatory ... Read more >>

Prostate (The Prostate)
[2021, 81(1):29-40]

Cited: 0 times

View full text PDF listing >>



A phase II randomized placebo-controlled trial of pomegranate fruit extract in men with localized prostate cancer undergoing active surveillance.

David Jarrard, Mikolaj Filon, Wei Huang, Tom Havighurst, Katina DeShong, KyungMann Kim, Badrinath R Konety, Daniel Saltzstein, Hasan Mukhtar, Barbara Wollmer, Chen Suen, Margaret G House, Howard L Parnes, Howard H Bailey,

<h4>Introduction or objective</h4>Men with favorable-risk prostate cancer (PCa) on active surveillance may benefit from intervention strategies to slow or prevent disease progression and the need for definitive treatment. Pomegranate and its extracts have shown antiproliferative and proapoptotic effects in cell lines and animal models, but its effect on human prostate ... Read more >>

Prostate (The Prostate)
[2021, 81(1):41-49]

Cited: 0 times

View full text PDF listing >>



Influence of pelvic lymph node dissection and node-positive disease on biochemical recurrence, secondary treatment, and survival after radical prostatectomy in men with prostate cancer.

Samuel L Washington, Janet E Cowan, Annika Herlemann, Kyle B Zuniga, Selma Masic, Hao G Nguyen, Peter R Carroll,

<h4>Background</h4>The benefit of pelvic lymph node dissection (PLND) at radical prostatectomy (RP) remains unclear given the low prevalence of known nodal disease (pN1) and concerns about its therapeutic utility.<h4>Objective</h4>To characterize the impact of PLND and secondary treatment on oncologic outcomes.<h4>Design, setting, and participants</h4>Cohort study of men who underwent primary RP ... Read more >>

Prostate (The Prostate)
[2021, 81(2):102-108]

Cited: 0 times

View full text PDF listing >>



The 26th Annual Prostate Cancer Foundation Scientific Retreat Report.

Andrea K Miyahira, Howard R Soule,

<h4>Background</h4>The 26th Annual Prostate Cancer Foundation (PCF) Scientific Retreat was held from October 24-26, 2019 in Carlsbad, CA.<h4>Methods</h4>The Annual PCF Scientific Retreat is a global scientific research conference that focuses on the most promising and interesting new research in the prostate cancer field, and topics arising from other fields that ... Read more >>

Prostate (The Prostate)
[2021, 81(1):3-19]

Cited: 0 times

View full text PDF listing >>



High intratumoral CD8+ T-cell infiltration is associated with improved survival in prostate cancer patients undergoing radical prostatectomy.

Yuanquan Yang, Kristopher Attwood, Wiam Bshara, James L Mohler, Khurshid Guru, Bo Xu, Pawel Kalinski, Gurkamal Chatta,

<h4>Background</h4>A high density of CD8<sup>+</sup> tumor infiltrating lymphocytes (TILs) is associated with improved survival in multiple cancers, but its prognostic role in prostate cancer remains controversial. The aim of our study was to evaluate the prognostic value of CD8<sup>+</sup> TILs in prostate cancer patients undergoing radical prostatectomy (RP). We hypothesized ... Read more >>

Prostate (The Prostate)
[2021, 81(1):20-28]

Cited: 0 times

View full text PDF listing >>



Androgen receptor signaling-targeted therapy and taxane chemotherapy induce visceral metastasis in castration-resistant prostate cancer.

Hiroaki Iwamoto, Kouji Izumi, Takashi Shimada, Hiroshi Kano, Suguru Kadomoto, Tomoyuki Makino, Renato Naito, Hiroshi Yaegashi, Kazuyoshi Shigehara, Yoshifumi Kadono, Atsushi Mizokami,

<h4>Background</h4>Visceral metastasis (VM), an important poor prognostic factor of prostate cancer (PC), is not commonly observed in castration sensitive status but is often observed after castration-resistant progression. However, the site, timing of emergence, and incidence of VM in castration-resistant patients have not yet been fully elucidated.<h4>Methods</h4>Demographic, surgical, pathological, and follow-up ... Read more >>

Prostate (The Prostate)
[2021, 81(1):72-80]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
0.9121 s